nach oben

European Surgery

Erschienen in:

01.10.2020 | review

Sentinel lymph node biopsy in breast cancer—an updated overview

verfasst von: Dr. Omar Hamdy, Omar Farouk, Adel El-Badrawy, Adel Denewer, Ahmed Setit

Erschienen in: European Surgery | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Summary

Background

Sentinel lymphadenectomy has replaced axillary lymph node dissection as a staging tool in early breast cancer. To be accepted as a standard of care, it had to pass successfully through a long journey which started in the early 1990s.

Methods

We carried out a comprehensive literature review focusing on the journey of the use of sentinel lymph node biopsy (SLNB) in breast cancer from its start until its current station, including the variable clinical applications, the current debates, and the future issues.

Results

Adoption of sentinel lymph node biopsy as a standard axillary staging procedure was a marvelous trend that helped to decrease the complications of axillary dissection and significantly improve the quality of life of patients with breast cancer. Various mapping techniques can be used for SLN localization, rendering oncology centers that have variable capabilities and preparations able to perform the procedure. This applies to specimen processing techniques as well. Many debates faced the researchers throughout the SLNB journey. They are all explained in the current article, in addition to the ongoing trials and the future aspects of SLNB in breast cancer.

Conclusion

Further research should be conducted to help resolve the clinical issues which are still debatable and to provide bases for improving the future trends which are progressing towards limiting the role of axillary dissection and axillary surgery to the minimum required level.

Vorheriger Artikel Closed-incision negative-pressure wound management in surgery—literature review and recommendations

Nächster Artikel Is fundoplication advisable in repair of para-oesophageal hernia? “Little operation” or “big operation”?

Motomura K. Sentinel node biopsy for breast cancer: past, present, and future. Breast Cancer. 2015;22:212–20. https://doi.org/10.1007/s12282-012-0421-7.CrossRefPubMed

He Z, Zhou Y, Wang F, Xu Q, Zhang W, Ni X, et al. Clinical value of postoperative sentinel lymph node biopsy. Ann Transl Med. 2019;7:683.PubMedPubMedCentral

Tsujimoto M. Recent advances in sentinel node biopsy in breast surgery. Breast Cancer. 2015;22:211.PubMed

Kuru B. The adventure of axillary treatment in early stage breast cancer. Turkish Federation of Breast Diseases Associations. Eur J Breast Health. 2020;16:1–15.PubMedPubMedCentral

Gould EA, Winship T, Philbin PH, Kerr HH. Observations on a “sentinel node” in cancer of the parotid. Cancer. 1960;13:77–8.PubMed

Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 1977;39:456–66.PubMed

Giuliano AE. The evolution of sentinel node biopsy for breast cancer: personal experience. Breast J. 2020;26:17–21. https://doi.org/10.1111/tbj.13729.CrossRefPubMed

Morton DL, Wen D‑R, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9.PubMed

Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391.PubMedPubMedCentral

10.

Krag D, Weaver D, Alex J, Fairbank J. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993; https://doi.org/10.1016/0960-7404(93)90064-6.CrossRefPubMed

11.

Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394–401.PubMedPubMedCentral

12.

Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg. 1997;226:271–8.PubMedPubMedCentral

13.

Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 1996;276:1818–22. https://doi.org/10.1001/jama.1996.03540220042028.CrossRefPubMed

14.

Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, et al. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008;247:207–13.PubMed

15.

Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7:983–90.PubMed

16.

Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23:4312–21.PubMed

17.

Ung OA. Australasian experience and trials in sentinel lymph node biopsy: the RACS SNAC trial. Asian J Surg. 2004;27:284–90.PubMed

18.

Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–53.PubMed

19.

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B‑32 randomised phase III trial. Lancet Oncol. 2007;8:881–8.PubMed

20.

Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98:599–609.PubMed

21.

Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240:462.PubMedPubMedCentral

22.

Canavese G, Catturich A, Vecchio C, Tomei D, Gipponi M, Villa G, et al. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol. 2009;20:1001–7.PubMed

23.

Maimaitiaili A, Liu Z, Wu D, Fan Z. Sentinel lymph node biopsy in breast cancer: current status and recent progress. Indian J Surg. 2020;82:84–9. https://doi.org/10.1007/s12262-019-02021-z.CrossRef

24.

Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595–600.PubMed

25.

Canavese G, Bruzzi P, Catturich A, Tomei D, Carli F, Garrone E, et al. Sentinel lymph node biopsy versus axillary dissection in node-negative early-stage breast cancer: 15-year follow-up update of a randomized clinical trial. Ann Surg Oncol. 2016;23:2494–500. https://doi.org/10.1245/s10434-016-5177-4.CrossRefPubMed

26.

Van der Ploeg IMC, Nieweg OE, Van Rijk MC, Olmos RAV, Kroon BBR. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008;34:1277–84.PubMed

27.

Fisher CS, Margenthaler JA, Hunt KK, Schwartz T. The landmark series: axillary management in breast cancer. Ann Surg Oncol. 2020;27:724–9. https://doi.org/10.1245/s10434-019-08154-5.CrossRefPubMed

28.

National Comprehensive Cancer Network. Breast Cancer (version 2.2020). 2020. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed Internet.

29.

Bernardi S, Bertozzi S, Londero AP, Angione V, Petri R, Giacomuzzi F. Prevalence and risk factors of intraoperative identification failure of sentinel lymph nodes in patients affected by breast cancer. Nucl Med Commun. 2013;34:664–73.PubMed

30.

Dordea M, Colvin H, Cox P, Nicolas AP, Kanakala V, Iwuchukwu O. Clinical and histopathological factors affecting failed sentinel node localization in axillary staging for breast cancer. Surgeon. 2013;11:63–6.PubMed

31.

Nowikiewicz T, Kurylcio A, Polkowski W, Zegarski W. Imaging methods for the local lymphatic system of the axilla in early breast cancer in patients qualified for sentinel lymph node biopsy. Prz Menopauzalny. 2016;15:52.PubMedPubMedCentral

32.

Chung A, Giuliano AE. Lymphatic mapping and sentinel Lymphadenectomy for breast cancer. In: Bland KI, Copeland EM, Klimberg VS, Gradishar W, The breast, 5th ed. USA: Elsevier; 2018. pp. 604–630.e6. http://www.sciencedirect.com/science/article/pii/B9780323359559000428.

33.

Abm Abdullah Al Hasan K, Hossain AFMA, Rahman A. Outcome of sentinel lymphnode biopsy with Methylene Blue dye in early stage Breast cancer. Eur J Surg Oncol. 2020;46:e31–e2. https://doi.org/10.1016/j.ejso.2019.11.044.CrossRef

34.

Nandu VV, Chaudhari MS. Efficacy of sentinel lymph node biopsy in detecting axillary metastasis in breast cancer using methylene blue. Indian J Surg Oncol. 2017;8:109–12.PubMed

35.

Kitai T, Inomoto T, Miwa M, Shikayama T. Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer. 2005; https://doi.org/10.2325/jbcs.12.211.CrossRefPubMed

36.

Goonawardena J, Yong C, Law M. Use of indocyanine green fluorescence compared to radioisotope for sentinel lymph node biopsy in early-stage breast cancer: systematic review and meta-analysis. Am J Surg. 2020; https://doi.org/10.1016/j.amjsurg.2020.02.001.CrossRefPubMed

37.

Wu X, Lin Q, Chen G, Lu J, Zeng Y, Chen X, et al. Sentinel lymph node detection using carbon nanoparticles in patients with early breast cancer. Plos One. 2015;10:e135714–e135714.PubMedPubMedCentral

38.

Zhang L, Huang Y, Yang C, Zhu T, Lin Y, Gao H, et al. Application of a carbon nanoparticle suspension for sentinel lymph node mapping in patients with early breast cancer: a retrospective cohort study. World J Surg Oncol. 2018;16:112. https://doi.org/10.1186/s12957-018-1414-6.CrossRefPubMedPubMedCentral

39.

Ahmed M, Purushotham AD, Douek M. Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review. Lancet Oncol. 2014; https://doi.org/10.1016/S1470-2045(13)70590-4.CrossRefPubMed

40.

Hamdy O, El-Badrawy A, Saleh GA, Metwally IH, Abdelwahab K, Farouk O, et al. Preoperative localization of sentinel lymph node in breast cancer patients by silver wire insertion or liquid charcoal injection guided by CT lymphography. Breast J. 2019; https://doi.org/10.1111/tbj.13511.CrossRefPubMed

41.

Nakagawa M, Morimoto M, Takechi H, Tadokoro Y, Tangoku A. Preoperative diagnosis of sentinel lymph node (SLN) metastasis using 3D CT lymphography (CTLG). Breast Cancer. 2016;23:519–24. https://doi.org/10.1007/s12282-015-0597-8.CrossRefPubMed

42.

Petropoulou T, Kapoula A, Mastoraki A, Politi A, Spanidou-Karvouni E, Psychogios I, et al. Imprint cytology versus frozen section analysis for intraoperative assessment of sentinel lymph node in breast cancer. Breast Cancer. 2017;9:325–30.PubMedPubMedCentral

43.

Marano A, Sodano B, Vitiello C, Martini AM, Baldassarre F, Siciliano A, et al. Sentinel lymph node biopsy with intraoperative touch imprint cytology (TIC) in breast cancer: experience of a mild-volume center. G Chir. 2020;41:94.PubMed

44.

de Boer M, van Deurzen CHM, van Dijck JAAM, Borm GF, van Diest PJ, Adang EMM, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med. 2009;361:653–63. https://doi.org/10.1056/NEJMoa0904832.CrossRefPubMed

45.

Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 2011;306:385–93.PubMedPubMedCentral

46.

Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297–305.PubMedPubMedCentral

47.

Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Harlow SP, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 2011;364:412–21. https://doi.org/10.1056/NEJMoa1008108.CrossRefPubMedPubMedCentral

48.

Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1385–93. https://doi.org/10.1016/S1470-2045(18)30380-2.CrossRefPubMed

49.

Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194–220.PubMed

50.

Lyman G, Giuliano A. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin. 2005;23:7703–20. https://doi.org/10.1200/JCO.2005.08.001.CrossRef

51.

Takei H, Suemasu K, Kurosumi M, Horii Y, Yoshida T, Ninomiya J, et al. Recurrence after sentinel lymph node biopsy with or without axillary lymph node dissection in patients with breast cancer. Breast Cancer. 2007;14:16–24.PubMed

52.

Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007;110:723–30.PubMed

53.

Zakaria S, Pantvaidya G, Reynolds CA, Grant CS, Sterioff S, Donohue JH, et al. Sentinel node positive breast cancer patients who do not undergo axillary dissection: Are they different? Surgery. 2008;143:641–7.PubMed

54.

Spiguel L, Yao K, Winchester DJ, Gorchow A, Du H, Sener SF, et al. Sentinel node biopsy alone for node-positive breast cancer: 12-year experience at a single institution. J Am Coll Surg. 2011;213:122–8.PubMed

55.

Park J, Fey JV, Naik AM, Borgen PI, Van Zee KJ, Cody HS III. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg. 2007;245:462.PubMedPubMedCentral

56.

Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27:2946–53.PubMed

57.

Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010;17:343–51.PubMedPubMedCentral

58.

Giuliano A, Hunt K, Ballman K. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2016;318:918–26. https://doi.org/10.1001/jama.2017.11470.CrossRef

59.

Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:423–6.

60.

Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318:918–26.PubMedPubMedCentral

61.

Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303–10.PubMedPubMedCentral

62.

Savolt A, Peley G, Polgar C, Udvarhelyi N, Rubovszky G, Kovacs E, et al. Eight-year follow up result of the OTOASOR trial: the Optimal Treatment Of the Axilla—Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43:672–9.PubMed

63.

Jang JK, Sverdlik ER, Schechter NR. A radiation oncologist’s guide to axillary management in breast cancer: a walk through the trials. Curr Breast Cancer Rep. 2019;11:293–302. https://doi.org/10.1007/s12609-019-00330-6.CrossRefPubMedPubMedCentral

64.

Kuru B, Yuruker S, Sullu Y, Gursel B, Ozen N. Management of the Axilla in T1‑2 breast cancer patients with macrometastatic sentinel node involvement who underwent breast-conserving therapy. J Investig Surg. 2019;32:48–54. https://doi.org/10.1080/08941939.2017.1375051.CrossRef

65.

Castelo M, Hu SY, Dossa F, Acuna SA, Scheer AS. Comparing observation, axillary radiotherapy, and completion axillary lymph node dissection for management of Axilla in breast cancer in patients with positive sentinel nodes: a systematic review. Ann Surg Oncol. 2020; https://doi.org/10.1245/s10434-020-08225-y.CrossRefPubMed

66.

Blackhall V, Bugelli M, Abbott N, Mullen R. The role of sentinel lymph node biopsy in planning adjuvant therapy for elderly women with low-risk breast cancer. Breast J. 2019; https://doi.org/10.1111/tbj.13577.CrossRefPubMed

67.

Tsuyuki S, Yamaguchi A, Kawata Y, Kawaguchi K. Assessing the effects of neoadjuvant chemotherapy on lymphatic pathways to sentinel lymph nodes in cases of breast cancer: Usefulness of the indocyanine green-fluorescence method. Breast. 2015;24:298–301. https://doi.org/10.1016/j.breast.2015.02.034.CrossRefPubMed

68.

Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from national surgical adjuvant breast and bowel project protocol B‑27. J Clin Oncol. 2005;23:2694–702. https://doi.org/10.1200/JCO.2005.05.188.CrossRefPubMed

69.

King TA, Morrow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol. 2015;12:335. https://doi.org/10.1038/nrclinonc.2015.63.CrossRefPubMed

70.

Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250:558–66.PubMed

71.

Classe J‑M, Loaec C, Gimbergues P, Alran S, de Lara CT, Dupre PF, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019;173:343–52. https://doi.org/10.1007/s10549-018-5004-7.CrossRefPubMed

72.

Hamdy O. Neoadjuvant therapy should be the standard of care for every node positive breast cancer patient. J Breast Cancer. 2019;22:149–52.PubMed

73.

Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32:1365–83.PubMed

74.

Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609–18.PubMed

75.

Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61.PubMedPubMedCentral

76.

Boileau J‑F, Poirier B, Basik M, Holloway CMB, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33:258–64.PubMed

77.

Tee SR, Devane LA, Evoy D, Rothwell J, Geraghty J, Prichard RS, et al. Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer. Br J Surg. 2018;105:1541–52. https://doi.org/10.1002/bjs.10986.CrossRefPubMed

78.

Boughey JC, Ballman KV, Le-Petross HT, McCall LM, Mittendorf EA, Ahrendt GM, et al. Identification and resection of the clipped node decreases the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy—results from ACOSOG Z1071. Ann Surg. 2016;263:802.PubMed

79.

Mamounas ETP. Optimal management of the axilla: a look at the evidence. Adv Surg. 2016;50:29–40.PubMed

80.

Franceschini G. Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer in patients with pre-treatment node-positive: Recommendations to optimize the performance. Eur J Surg Oncol. 2020;46:216–7. https://doi.org/10.1016/j.ejso.2019.10.020.CrossRefPubMed

81.

Sun X, Wang X‑E, Zhang Z‑P, Shi Z‑Q, Cong B‑B, Wang Y‑S, et al. Neoadjuvant therapy and sentinel lymph node biopsy in HER2-positive breast cancer patients: results from the PEONY trial. Breast Cancer Res Treat. 2020;180:423–8. https://doi.org/10.1007/s10549-020-05559-9.CrossRefPubMed

82.

Donker M, Straver ME, Wesseling J, Loo CE, Schot M, Drukker CA, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261:378–82.PubMed

83.

van Nijnatten TJA, Simons JM, Smidt ML, van der Pol CC, van Diest PJ, Jager A, et al. A novel less-invasive approach for axillary staging after neoadjuvant chemotherapy in patients with axillary node-positive breast cancer by combining radioactive iodine seed localization in the Axilla with the sentinel node procedure (RISAS): a Dutch pros. Clin Breast Cancer. 2017;17:399–402.PubMed

84.

Balasubramanian R, Morgan C, Shaari E, Kovacs T, Pinder SE, Hamed H, et al. Wire guided localisation for targeted axillary node dissection is accurate in axillary staging in node positive breast cancer following neoadjuvant chemotherapy. Eur J Surg Oncol. 2020;46:1028–33. https://doi.org/10.1016/j.ejso.2019.12.007.CrossRefPubMed

85.

Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072–8.PubMedPubMedCentral

86.

García-Moreno JL, Benjumeda-Gonzalez AM, Amerigo-Góngora M, Landra-Dulanto PJ, Gonzalez-Corena Y, Gomez-Menchero J. Targeted axillary dissection in breast cancer by marking lymph node metastasis with a magnetic seed before starting neoadjuvant treatment. J Surg Case Rep. 2019; https://doi.org/10.1093/jscr/rjz344.CrossRefPubMedPubMedCentral

87.

Natsiopoulos I, Intzes S, Liappis T, Zarampoukas K, Zarampoukas T, Zacharopoulou V, et al. Axillary lymph node tattooing and targeted axillary dissection in breast cancer patients who presented as cN+ before neoadjuvant chemotherapy and became cN0 after treatment. Clin Breast Cancer. 2019;19:208–15.PubMed

88.

Sun SX, Moseley TW, Kuerer HM, Yang WT. Imaging-based approach to axillary lymph node staging and sentinel lymph node biopsy in patients with breast cancer. AJR Am J Roentgenol. 2019;214:249–58. https://doi.org/10.2214/AJR.19.22022.CrossRefPubMed

89.

Wu S, Wang Y, Li J, Zhang N, Mo M, Klimberg S, et al. Subtype-guided (18)F-FDG PET/CT in tailoring axillary surgery among patients with node-positive breast cancer treated with neoadjuvant chemotherapy: a feasibility study. Oncologist. 2020;25:e626. https://doi.org/10.1634/theoncologist.2019-0583.CrossRefPubMed

90.

Alliance for Clinical Trials in Oncology. Comparison of axillary lymph node dissection with axillary radiation for patients with node-positive breast cancer treated with chemotherapy (alliance A011202). 2020. https://clinicaltrials.gov/ct2/show/NCT01901094.

91.

NSABP Foundation Inc. Standard or comprehensive radiation therapy in treating patients with early-stage breast cancer previously treated with chemotherapy and surgery. https://clinicaltrials.gov/ct2/show/NCT01872975.

92.

de Boniface J, Frisell J, Andersson Y, Bergkvist L, Ahlgren J, Ryden L, et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer. 2017;17:379.PubMedPubMedCentral

93.

de Boniface J, Ahlgren J, Andersson Y, Bergkvist L, Frisell J, Lundstedt D, et al. The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer. Breast Cancer Res Treat. 2020;180:167–76. https://doi.org/10.1007/s10549-020-05537-1.CrossRefPubMedPubMedCentral

94.

Goyal A, Dodwell D. POSNOC: a randomised trial looking at axillary treatment in women with one or two sentinel nodes with macrometastases. Clin Oncol. 2015;27:692–5. https://doi.org/10.1016/j.clon.2015.07.005.CrossRef

95.

Gentilini O, Veronesi U. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). Breast. 2012;21:678–81.PubMed

96.

Henke G, Knauer M, Ribi K, Hayoz S, Gérard M‑A, Ruhstaller T, et al. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. Trials. 2018;19:667. https://doi.org/10.1186/s13063-018-3021-9.CrossRefPubMedPubMedCentral

97.

Tamaki Y. Clinical usefulness of one-step nucleic acid amplification assay in the new era of sentinel lymph node biopsy for breast cancer. Breast Cancer Manag. 2015;4:7–15. https://doi.org/10.2217/bmt.14.50.CrossRef

98.

Fougo JL, Amendoeira I, Brito MJ, Correia AP, Gonçalves A, Honavar M, et al. Sentinel node total tumour load as a predictive factor for non-sentinel node status in early breast cancer patients—The porttle study. Surg Oncol. 2020;32:108–14. http://www.sciencedirect.com/science/article/pii/S0960740419304736.PubMed

99.

Shi F, Zhang Q, Liang Z, Zhang M, Liu X. One-step nucleic acid amplification assay is an accurate technique for sentinel lymph node biopsy of breast cancer patients: a meta-analysis. Br J Cancer. 2017;117:1185–91.PubMedPubMedCentral

100.

Shi F, Liang Z, Zhang Q, Wang C, Liu X. The performance of one-step nucleic acid amplification assay for intraoperative detection of sentinel lymph node macrometastasis in breast cancer: an updated meta-analysis. Breast. 2018;39:39–45. http://www.sciencedirect.com/science/article/pii/S0960977618300535.PubMed

Titel: Sentinel lymph node biopsy in breast cancer—an updated overview
verfasst von: Dr. Omar Hamdy
Omar Farouk
Adel El-Badrawy
Adel Denewer
Ahmed Setit
Publikationsdatum: 01.10.2020
Verlag: Springer Vienna
Erschienen in: European Surgery / Ausgabe 6/2020
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI: https://doi.org/10.1007/s10353-020-00665-w

Springer Medizin Österreich

Summary

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

Closed-incision negative-pressure wound management in surgery—literature review and recommendations

Telemedicine in the COVID-19 era: the new normal

Universal seasonal snow globe surgery report

Quality of colon resection results in Upper Austria based on a prospective database

Refractory hypoglycemia associated with giant solitary fibrous tumor of the pleura (Doege–Potter syndrome)

Fibroblast growth factor 8 overexpression is predictive of poor prognosis in pancreatic ductal adenocarcinoma